Lilly's board undergoes more changes; Merck strategy chief joins Roger...
→ Eli Lilly has appointed Procter & Gamble CEO Jon Moeller to the board of directors, while Goldman Sachs operating partner Karen Walker will resign from the board on Dec. 31 ...
View ArticleNabla Bio moves closer to AI-created antibodies
Protein-making AI models have fueled the launch of a $1 billion startup and a Nobel Prize win in 2024, but are they ready to actually make drugs? Leaders of some of the largest startups working ...
View ArticleLexicon ends commercial work to focus on R&D
Lexicon Pharmaceuticals is reverting to a clinical development company after facing repeated setbacks at the FDA for its type 1 diabetes and chronic kidney disease drug. The Texas biotech is slashing...
View ArticleHalozyme withdraws €2B Evotec acquisition proposal
Halozyme Therapeutics said Friday that it has pulled its proposal to buy Evotec, a struggling German biotech that Halozyme said was "unwilling to engage" in deal talks. Last week, San Diego ...
View ArticleFrom vaccines to psychedelics, five drugmakers on what could change under a...
President-elect Donald Trump and Robert Kennedy, Jr. — his pick to head up the Department of Health and Human Services — were hot topics at the Jefferies London Healthcare Conference this week as...
View ArticleSenate committee advances pharma patent challenge bill
The Senate Judiciary Committee narrowly advanced a bill Thursday that would change the way the Patent Trial and Appeal Board operates, limiting the ability of parties to challenge patents in court and...
View ArticleDrug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders
Eli Lilly and Novo Nordisk have filed dozens of lawsuits against compounding pharmacies marketing their own versions of popular weight loss and diabetes drugs. A new legal strategy could put Lilly one...
View ArticleSanofi introduces new 340B payment model — report
Sanofi is proposing a new model for distributing drug discounts under the federal 340B program, according to the Wall Street Journal, in an effort that is almost certain to create pushback ...
View ArticleFDA approves BridgeBio's heart disease drug, setting up competition with...
The FDA approved BridgeBio’s acoramidis in a rare, genetic heart disease that’s expected to become an intense area of market competition, and a broad label will give it a near-immediate boost against...
View ArticleTrump picks Johns Hopkins researcher Marty Makary to lead the FDA
President-elect Donald Trump selected Marty Makary to lead the FDA, choosing a Johns Hopkins University surgeon who has called the US government the “greatest perpetrator of misinformation during the...
View ArticleTrump picks former congressman and vaccine injury advocate to lead CDC
Physician, veteran and former Florida Congressman Dave Weldon is President-elect Donald Trump’s pick to lead the CDC, giving Robert F. Kennedy Jr. a key ally in his planned review of the safety of...
View ArticleTrump announces picks for FDA, CDC; Novartis seeks bolt-on deals, raises...
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add...
View ArticleAstraZeneca’s Truqap edges closer to prostate cancer label expansion with...
After recently discontinuing R&D for Truqap in triple-negative breast cancer, AstraZeneca has some good news on its kinase inhibitor in a different indication. The UK drugmaker said Truqap...
View ArticleADC biotech Adcendo nabs $135M Series B as it enters the clinic
Danish biotech Adcendo is joining the antibody-drug conjugate megaround train. Adcendo has corralled a $135 million Series B led by TCGX. And according to an Endpoints News tally, of the 88 biotech...
View ArticleGilead buys experimental HIV vaccines from a small Barcelona biotech
Long known for its HIV drugs, Gilead is further delving into the field by acquiring investigational vaccines for the stubborn virus from a little-known biotech in Spain. Gilead is paying an undisclosed...
View ArticleReplimune aims to raise $125M; Otsuka makes another deal with Ionis
Plus, news about Kanglin Biotechnology, Seelos, Orbus and Sonata: Replimune’s $125M offering: The biotech announced the offering four days after it submitted an FDA application for RP1 ...
View ArticleBiohaven's myostatin inhibitor misses primary endpoint in spinal muscular...
Biohaven’s stock fell in premarket trading on Monday after it announced a Phase 3 trial failure of its myostatin inhibitor in spinal muscular atrophy and obesity. The RESILIENT study did not ...
View ArticleCassava shares plunge as controversial Alzheimer’s drug fails Phase 3 trial
Is this the end for Cassava Sciences? After a problematic development path riddled with allegations of misleading investors, the biotech’s Alzheimer’s drug flopped on all endpoints in a Phase 3 study....
View Article#ASH24: Incyte touts Monjuvi data from Phase 3 follicular lymphoma trial as...
Incyte’s monoclonal antibody Monjuvi reduced certain follicular lymphoma patients’ risk of progression, relapse or death by 57% compared to placebo, the company announced Monday. The Phase 3 data,...
View ArticleMerck halts Phase 3 trial with PAH drug Winrevair following positive interim...
Merck is stopping a Phase 3 trial of its pulmonary arterial hypertension treatment Winrevair almost a year early following positive interim data, the company announced Monday. The trial, which was...
View Article